CA2485984A1 - Nouvelle combinaison - Google Patents

Nouvelle combinaison Download PDF

Info

Publication number
CA2485984A1
CA2485984A1 CA002485984A CA2485984A CA2485984A1 CA 2485984 A1 CA2485984 A1 CA 2485984A1 CA 002485984 A CA002485984 A CA 002485984A CA 2485984 A CA2485984 A CA 2485984A CA 2485984 A1 CA2485984 A1 CA 2485984A1
Authority
CA
Canada
Prior art keywords
methyl
inhibitor
dihydro
hypertension
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002485984A
Other languages
English (en)
Inventor
David Nathan Abraham Fox
Bernadette Hughes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211919A external-priority patent/GB0211919D0/en
Priority claimed from GB0229784A external-priority patent/GB0229784D0/en
Application filed by Individual filed Critical Individual
Publication of CA2485984A1 publication Critical patent/CA2485984A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des combinaisons qui contiennent : a) un inhibiteur de phosphodiestérase de type 5 (PDE5) spécifique de la guanosine monophosphate cyclique (GMPc) ; et b) un inhibiteur de l'enzyme de conversion de l'angiotensine (ACE). Ces combinaisons sont utiles pour le traitement de l'hypertension.
CA002485984A 2002-05-23 2003-05-09 Nouvelle combinaison Abandoned CA2485984A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0211919A GB0211919D0 (en) 2002-05-23 2002-05-23 Novel combination
GB0211919.6 2002-05-23
GB0229784A GB0229784D0 (en) 2002-12-20 2002-12-20 Novel combination
GB0229784.4 2002-12-20
PCT/IB2003/001889 WO2003099194A2 (fr) 2002-05-23 2003-05-09 Nouvelle combinaison

Publications (1)

Publication Number Publication Date
CA2485984A1 true CA2485984A1 (fr) 2003-12-04

Family

ID=29585817

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002485984A Abandoned CA2485984A1 (fr) 2002-05-23 2003-05-09 Nouvelle combinaison

Country Status (18)

Country Link
EP (1) EP1506015A2 (fr)
JP (1) JP2005529927A (fr)
KR (1) KR20050004195A (fr)
CN (1) CN1655820A (fr)
AR (1) AR040090A1 (fr)
AU (1) AU2003223071A1 (fr)
BR (1) BR0311191A (fr)
CA (1) CA2485984A1 (fr)
IL (1) IL164975A0 (fr)
MX (1) MXPA04010951A (fr)
NO (1) NO20045517L (fr)
PA (1) PA8574201A1 (fr)
PE (1) PE20040514A1 (fr)
PL (1) PL374198A1 (fr)
RU (1) RU2004133973A (fr)
TW (1) TW200407153A (fr)
UY (1) UY27816A1 (fr)
WO (1) WO2003099194A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
GB0318094D0 (en) * 2003-08-01 2003-09-03 Pfizer Ltd Novel combination
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (fr) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Utilisation des inhibiteurs de PDE III pour la réduction de la taille du coeur chez des mammifères souffrant d'insufficances cardiaques
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
FR2902009B1 (fr) * 2006-06-13 2012-12-07 Bioprojet Soc Civ Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
JP2010501577A (ja) 2006-08-24 2010-01-21 サーフェイス ロジックス，インコーポレイティド 薬物動態が改善された化合物
EP1920785A1 (fr) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Préparation liquide contenant un complexe du pimobendane et de la cyclodextrine
EP3167876B1 (fr) 2012-03-15 2021-09-08 Boehringer Ingelheim Vetmedica GmbH Formulation de comprimé pharmaceutique pour le secteur vétérinaire, son procédé de production et d'utilisation
EP3021832B9 (fr) 2013-07-19 2023-03-15 Boehringer Ingelheim Vetmedica GmbH Dérivés de la cyclodextrine éthérifiée préservés contenant une composition pharmaceutique liquide aqueuse
CA2930033C (fr) 2013-12-04 2022-12-13 Boehringer Ingelheim Vetmedica Gmbh Compositions pharmaceutiques ameliorees de pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US6362178B1 (en) * 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AP2002002455A0 (en) * 1999-10-11 2002-06-30 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.

Also Published As

Publication number Publication date
PL374198A1 (en) 2005-10-03
MXPA04010951A (es) 2005-06-08
JP2005529927A (ja) 2005-10-06
AU2003223071A1 (en) 2003-12-12
NO20045517L (no) 2004-12-17
PE20040514A1 (es) 2004-08-24
IL164975A0 (en) 2005-12-18
KR20050004195A (ko) 2005-01-12
UY27816A1 (es) 2003-12-31
BR0311191A (pt) 2005-03-01
PA8574201A1 (es) 2003-12-19
WO2003099194A2 (fr) 2003-12-04
CN1655820A (zh) 2005-08-17
WO2003099194A3 (fr) 2004-06-03
TW200407153A (en) 2004-05-16
AR040090A1 (es) 2005-03-16
RU2004133973A (ru) 2005-09-10
EP1506015A2 (fr) 2005-02-16

Similar Documents

Publication Publication Date Title
EP2531187B1 (fr) Stimulateurs de sgc ou activateurs de sgc seuls ou en combinaison avec des inhibiteurs de pde5 pour le traitement de la mucoviscidose
US20040186046A1 (en) Treatment of type 1 diabetes with PDE5 inhibitors
KR20030023747A (ko) 인슐린 저항성 증후군의 치료
CA2485984A1 (fr) Nouvelle combinaison
CA2474852A1 (fr) Utilisation d'inhibiteurs pde5 dans le traitement de la cicatrisation et de la fibrose
CA2491002A1 (fr) Nouvelle combinaison
US20050049255A1 (en) Therapeutic combinations
US20040132731A1 (en) Novel combination
US20040077624A1 (en) Novel combination
JP2006520777A (ja) Ｐｄｅ５阻害剤を用いる１型糖尿病の治療
WO2005011727A1 (fr) Combinaison d'un activateur de cyclase de guanylate soluble et d'un inhibiteur d'ace utile dans le traitement d'un trouble cardio-vasculaire ou metabolique
WO2005042022A2 (fr) Combinaison nouvelle
US20050059660A1 (en) Novel combination
WO2003047588A1 (fr) Necessaire pour reduire la douleur provoquee par les inhibiteurs des pde-v
EP1157705A2 (fr) Utilisation d'un inhibiteur de la phosphodiestérase dans la fabrication d'un médicament destiné à la stabilisation de la pression sanguine lors de l'hémodialyse
US20020065286A1 (en) Treatment of wounds
AU2001276636A1 (en) Treatment of wounds
JP4533590B2 (ja) 脊髄損傷患者における疼痛又は痙性軽減用医薬組成物
HK1076380A (en) Pharmaceutical combination of pde5 inhibitors with ace inhibitors
HK1077219A (en) Combination of pde5 inhibitors with angiotensin ii receptor antagonists

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued